Sunny Malhotra Sareen I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Email Sunny Malhotra Sareen LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca I am a biomedical researcher who serves as the Principal Investigator at the Clinical Neuroimmunology Unit of the Vall d'Hebron Research Institute.
As the Principal Investigator, I have a strong commitment to Translational Research and a solid background in biomedical sciences. My expertise lies in the discovery of biomarkers through genetic indicators and gene expression, particularly in identifying new therapeutic targets for neurological diseases. Additionally, I have over a decade of involvement in pharmacogenetics, genomics, and inflammasome biology studies. I have received training from various institutions, including the National Institute of Immunology (New Delhi), the Institute of Genomics and Integrative Biology (New Delhi), Progenika Biopharma, and UKE Hamburg. Dr. Malhotra has developed research lines funded by the Carlos III Health Institute during the periods 2017-2019 and 2021-2024. Selected awards/grants granted to the PI include: "Novartis Award" for the best oral communication; "Extraordinary Award" of the year for his "Doctorate" (UPF); "Merck Solidarity Award" for multiple sclerosis of the year; "Hope Award" for multiple sclerosis of the year; "Marie Curie Fellowship": as a predoctoral researcher; "Educational Fellowship": from ECTRIMS (Boston); "PERIS Fellowship": as a postdoctoral researcher. I serve as a lecturer and have extensive experience reviewing research articles in international journals. I am a member of various scientific editorial committees and have supervised master's and doctoral theses with 'Cum Laude' honors. I am a member of the Human Resources Strategy for Researchers (HRS4R) Committee at the center, with the main motto of promoting excellence in science in Europe. In general, my primary research focus includes neuroinflammatory/neurodegenerative diseases and the search for new biomarkers/therapeutic target objectives and drug discovery.
Projects TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas IP: Begoña Benito Villabriga Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala Funding agency: Instituto de Salud Carlos III Funding: 2494527.53 Reference: FORT23/00034 Duration: 01/01/2024 - 31/12/2027 SGR-Cat 2021: Neuroimmunologia Clínica IP: Xavier Montalban Gairín Collaborators: Ana Isabel Guerrero Perez, Carlos Nos Llopis, Sunny Malhotra Sareen, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Marta Rodríguez Barranco, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Javier Villacieros Álvarez, Rafael Garcia Merida, Maria Arantza Dema Etxezarreta, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 00782 Duration: 01/01/2022 - 30/06/2025 Liquid biopsy in multiple sclerosis: A non-invasive approach for disease prognosis and drug discovery... IP: Sunny Malhotra Sareen Collaborators: Jordi Rio Izquierdo, Ana Zabalza de Torres, Rucsanda Pinteac Funding agency: Instituto de Salud Carlos III Funding: 140360 Reference: PI20/01697 Duration: 01/01/2021 - 30/06/2025 NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients IP: Sunny Malhotra Sareen Collaborators: - Funding agency: Fundación Merck Salud Funding: 0.01 Reference: MERCK/PREM.SOLIDARIS/2020/MALHOTRA Duration: 18/12/2020 - 18/12/2020 Pagination Current page 1 Page 2 Page 3 Page 4 Next page › Last page »
